Medicare Compliance & Reimbursement - 2007 Issue 33
READER QUESTION: Don't Let Fear Of Denials Keep You From Billing Monthly A1C Tests
Subscribe or sign in to view the full article.
Article Overview
This reader Q&A explains how a Medicare coverage policy applies to repeated hemoglobin A1C testing and why billing frequency depends on the patient’s clinical situation. It is aimed at coders, billers, and practice staff who work with diabetes laboratory services, Medicare claims, and diagnosis coding. The article also references a CLIA-waived test modifier and highlights the importance of matching diabetes diagnosis coding to the patient’s level of control and related manifestations.
Why This Topic Matters
Frequent A1C testing can trigger claim denials if coverage policy, laboratory status, or diagnosis coding do not support the service. Understanding the article’s scope helps revenue cycle staff identify when the guidance applies and where coding accuracy matters most.
What You Will Learn
- How Medicare coverage policy relates to repeated hemoglobin A1C testing
- What general factors affect the frequency of A1C testing
- Why CLIA-waived laboratory status may be relevant to billing
- How diagnosis coding for diabetes control status affects claim support
- Why related diabetes manifestations should be coded carefully
Who Should Read This
- Medical coders
- Medical billers
- Revenue cycle staff
- Compliance staff
- Primary care practices
- Endocrinology practices
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com